NCT00258778View on ClinicalTrials.gov

Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 30, 2005

Study Completion Date

January 31, 2006

Conditions
Gaucher Disease
Interventions
DRUG

Human Glucocerebrosidase (prGCD)

All Listed Sponsors
lead

Protalix

INDUSTRY

NCT00258778 - Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD) | Biotech Hunter | Biotech Hunter